We compared the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, doxycycline, and minocycline by broth microdilution against 76 isolates belonging to seven species of rapidly growing mycobacteria (RGM) and 45 isolates belonging to five species of slowly growing nontuberculous mycobacteria (NTM). By using a resistance breakpoint of >4 g/ml for tigecycline and >8 g/ml for tetracycline, all RGM were highly susceptible to tigecycline, with inhibition of 50% of isolates at <0.12 g/ml and inhibition of 90% of isolates at 0.25 g/ml for Mycobacterium abscessus and inhibition of both 50 and 90% of isolates at <0.12 g/ml for M. chelonae and the M. fortuitum group. The MICs of tigecycline were the same for tetracycline-resistant and -susceptible strains, and RGM isolates were 4-to 11-fold more susceptible to tigecycline than to the tetracyclines. In contrast, no slowly growing NTM were susceptible to tigecycline, and isolates of M. marinum and M. kansasii were less susceptible to this agent than to minocycline. This new antimicrobial offers exciting therapeutic potential for the RGM, especially for isolates of the M. chelonae-M. abscessus group, against which the activities of the currently available drugs are limited.
Treatment of infections due to rapidly growing mycobacteria (RGM) remains difficult, in part because of resistance to the first-line antituberculous agents and also in part because of resistance to almost all antibacterial agents (3, 21) . The only drugs with activity against all three major pathogenic species (Mycobacterium chelonae, M. abscessus, and M. fortuitum) are amikacin (13) and clarithromycin (4) . In vitro studies with prior glycylcyclines (N,N-dimethylglycylamido-minocycline [DMG-MINO] and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline [DMG-DMDOT]) have shown this class of agents to be extremely active against this group of organisms, including tetracycline-resistant strains (1, 3) . The latest glycylcycline, tigecycline (GAR-936), has shown excellent activity against many tetracycline-resistant bacterial species (1, 8, 17; R. N. Jones, A. C. Gales, L. M. Deshpande, D. M. Johnson, and D. J. Biedenbach, poster 407, 39th Intersci. Conf. Antimicrob. Agents Chemother., 1999). With this in mind, we undertook a comparative study of the in vitro susceptibilities of multiple species of nontuberculous mycobacteria (NTM) to tetracycline, minocycline, doxycycline, and tigecycline.
(A portion of this study was presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 16 Isolates of the M. fortuitum group, M. chelonae, and M. abscessus were identified to the species level by using drug susceptibility patterns (3, 11) or by PCR-restriction enzyme analysis (PRA) of a 439-bp sequence (Telenti fragment) of the 65-kDa hsp gene (12, 15) . The remaining RGM species were identified only by PRA (2, 23) . Isolates of slowly growing NTM were identified by use of a commercial DNA-RNA probe (Accu-Probe) (Gen-Probe, Inc) or PRA of the 65-kDa hsp gene (15) .
Susceptibility testing. The isolates were tested for their susceptibilities to tetracycline, minocycline, doxycycline, and tigecycline (formerly GAR-936; Wyeth-Ayerst, Pearl River, N.Y.). MICs were determined by broth microdilution and a recently published tentative NCCLS standard method for mycobacterial susceptibility testing of RGM and slowly growing NTM (10) . The resistance breakpoints were Ն16 g/ml for tetracycline, doxycycline, and minocycline (9) . For slowly growing NTM, the NCCLS document does not deal with breakpoints for tetracycline, and breakpoints for doxycycline and minocycline are given only for M. marinum. The breakpoints for the three tetracyclines used here are those for bacterial species that grow aerobically (9) . The resistance breakpoint tentatively recommended by the manufacturer for tigecycline is Ն8 g/ml.
Quality control. Quality control for the tetracyclines and tigecycline were performed by using Staphylococcus aureus ATCC 29213 and suggested quality control ranges recommended by the NCCLS for the tetracyclines or the manufacturer for tigecycline (9) . Acceptable MIC ranges for S. aureus ATCC 29213 are 0.03 to 0.12 g/ml for tigecycline, 0.12 to 0.5 g/ml for doxycycline, 0.06 to 0.5 g/ml for minocycline, and 0.25 to 1 g/ml for tetracycline. All quality control results were within the acceptable ranges.
RESULTS
Results for the clinical isolates of the common pathogenic species of the RGM are shown in Tables 1 and 2 . In general, the MICs of tigecycline for all isolates were very low, with comparable values for tetracycline-susceptible and tetracycline-resistant strains.
For tetracycline-susceptible strains, tigecycline was approximately 4 dilutions more active than the older tetracyclines. For 15 of 16 tetracycline-susceptible M. fortuitum strains, the tetracycline MICs were 0.5 to 8.0 g/ml, with the mode tetracycline MIC being 0.5 g/ml. In contrast, for 15 of the 16 isolates the tigecycline MICs were Յ0.12 g/ml, with the mode tigecycline MIC being Յ0.06 g/ml (16-fold more active than tetracycline) (data not shown). Similar results were seen with M. chelonae and a single strain of M. immunogenum. For the four tetracycline-susceptible isolates tetracycline MICs were 1 to 4 g/ml (mode, 4 g/ml), while the tigecycline MICs for the same strains ranged from Յ0.06 to 0.25 g/ml (mode, Յ0.06 g/ml) (data not shown). Minocycline and doxycycline were more active against the tetracycline-susceptible strains, with modes of Յ0.12 and Յ0.25 g/ml, respectively. For approximately 50% of the isolates, however, minocycline MICs were in the range of 0.25 to 4. 0 g/ml, which were 3 to 6 dilutions higher than those of tigecycline.
Results for the five RGM reference strains are given in Table 3 . Included are MICs of two glycylcyclines for these strains published previously (3). The activities of tigecycline against these strains were the same as those of DMG-DMDOT and comparable to those of DMG-MINO, with results similar to those achieved for the clinical isolates. This is in contrast to the results for staphylococcal species, against which minocycline is 1 to 4 dilutions more active than tigecycline (1).
All 33 strains of six species of slowly growing NTM were resistant to tigecycline (MICs, 16 to Ͼ32 g/ml) ( Table 4) . Minocycline was more active than tigecycline against the closely related photochromogenic species M. marinum and M. kansasii. Single isolates each of M. xenopi and M. simiae were also resistant to tigecycline (MICs, 16 and Ͼ32 g/ml, respectively) (data not shown in Table 4 ). Additional numbers of test isolates of the latter two species are needed to establish the apparent lack of activity of tigecycline.
DISCUSSION
The tetracyclines have been highly popular for antimicrobial therapy because of their activities against numerous bacterial organisms, although their use has declined dramatically in the past decade because of drug resistance. Some of the clinical isolates against which tetracyclines exhibit activities include some species of RGM such as M. fortuitum, M. smegmatis, and M. mucogenicum (6, 20, 21, 22) , 50% or more clinical isolates of which are susceptible. However, at clinically achievable levels these agents are less effective against other common pathogenic species of RGM such as M. chelonae (26% of isolates are susceptible to doxycycline at 4 g/ml) and M. abscessus (4% of isolates are susceptible to doxycycline at 4 g/ml) (13, 18) . Preliminary studies suggest that these species contain a number of resistance determinants that likely play a role in this resistance (11) .
The introduction of the glycylcyclines represents a significant advance in the tetracyclines, as the glycylcyclines are unaffected by the major genetic mechanisms (efflux, ribosomal protection) responsible for tetracycline resistance among bacterial species (14, 16) . Previous studies with two early glycylcyclines, DMG-MINO and DMG-DMDOT, showed that they have excellent in vitro activities against all species of RGM including the members of the M. fortuitum group, M. chelonae, M. abscessus, and M. mucogenicum (3) . These results were comparable to the results obtained in the present study with a The resistance breakpoints used were Ն8 g/ml for tigecycline and Ն16 g/ml for the three older tetracyclines.
b The values in parentheses are the number of isolates tested. (3), values which are also the same as those of tigecycline for the 20 isolates tested in the present study.
The activity of tigecycline could be highly useful clinically, especially against RGM species causing serious disease, before susceptibilities are available. Amikacin is the only agent with activity against all RGM species, but it has major renal and auditory toxicities. Tigecycline also has much anticipated usefulness against M. abscessus isolates causing chronic lung disease. The latter disease is incurable with currently available drugs (19) . It is increasingly problematic in patients with cystic fibrosis, in whom subsequent transplantation with its associated immune suppression can result in disseminated disease (5, 7) . In contrast, tigecycline appears to have no in vitro activity against any of the species of slowly growing NTM studied, including those species (M. marinum, M. kansasii) that were minocycline susceptible at the currently suggested resistance breakpoints. Experience with MIC testing and specific MIC breakpoints is limited for many slowly growing species, however, especially less commonly encountered species such as M. xenopi and M. simiae. This shortcoming will require additional future studies, an observation recognized in the recent NCCLS document on mycobacterial susceptibility testing (10) .
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